A Phase 1 Dosing Study of Ruxolitinib in Children with Relapsed or Refractory Solid tumors, Leukemias, or Myeloproliferative Neoplasms: A Children's Oncology Group Phase 1 Consortium Study (ADVL1011)

BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations. PROCEDURE: A phase 1 trial of ruxolitinib was performed to determine the maximum-tolerated or recommended phase 2 dose, dose-limiting toxicities (DLTs), pharmacokinetics (P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Loh, Mignon L., Tasian, Sarah K., Rabin, Karen R., Brown, Patrick, Magoon, Daniel, Reid, Joel M., Chen, Xuejun, Ahern, Charlotte H., Weigel, Brenda J., Blaney, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546537/
https://ncbi.nlm.nih.gov/pubmed/25976292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25575
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados